Pasithea Therapeutics (KTTA) Income from Continuing Operations (2021 - 2026)
Pasithea Therapeutics recorded quarterly Income from Continuing Operations of 2869482.0 in Q1 2026, up 71.62% quarter-over-quarter from 10110868.0 in Q4 2025, and up 19.47% year-over-year from 2401846.77 in Q1 2025.
Pasithea Therapeutics' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 2869482.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 19.47% year-over-year to 2869482.0; the TTM figure through Mar 2026 stood at 19733927.0 (down 45.03% YoY), while the FY2025 annual figure was 20427683.0, down 46.91% from the prior year.
- Income from Continuing Operations came in at 2869482.0 for Q1 2026 at Pasithea Therapeutics, up from 10110868.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1574240.0 in Q1 2022 to a low of 10110868.0 in Q4 2025.
- A 5-year average of 3806943.59 and a median of 3598084.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 743.25% in 2022 and soared 36.84% in 2024, its largest moves.
- Pasithea Therapeutics' Income from Continuing Operations stood at 4053404.0 in 2022, then retreated by 24.12% to 5031264.0 in 2023, then jumped by 36.84% to 3177661.0 in 2024, then sank by 218.19% to 10110868.0 in 2025, then soared by 71.62% to 2869482.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2869482.0, 10110868.0, and 3037420.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | -2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.87 Mn |
| Dec 31, 2025 | -10.11 Mn |
| Sep 30, 2025 | -3.04 Mn |
| Jun 30, 2025 | -3.72 Mn |
| Mar 31, 2025 | -3.56 Mn |
| Dec 31, 2024 | -3.18 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -3.87 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | -5.03 Mn |
| Sep 30, 2023 | -3.61 Mn |
| Jun 30, 2023 | -3.60 Mn |
| Mar 31, 2023 | -3.27 Mn |
| Dec 31, 2022 | -4.05 Mn |
| Sep 30, 2022 | -4.19 Mn |
| Jun 30, 2022 | -2.19 Mn |
| Mar 31, 2022 | -1.57 Mn |
| Dec 31, 2021 | 630,143.00 |
| Sep 30, 2021 | -1.53 Mn |
| Jun 30, 2021 | -727,947.00 |
| Mar 31, 2021 | -549,609.00 |